Trial reportCancer2025
Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL-1 study.
Trial report in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
64407564MMY1001: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
Who cites it
7 citing papers in PubMed.
- Health-related quality of life with linvoseltamab treatment for relapsed/refractory multiple myeloma in LINKER-MM1.Blood neoplasia · 2026Trial
- Trial
- Dermatologic Adverse Events Associated with T-Cell Engager Therapy.American journal of clinical dermatology · 2026Review
- Supportive care for talquetamab-related dysgeusia in multiple myeloma: mixed-methods evidence, nutrition-focused flowchart, and digital companion concept.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Reshaping the definition of high-risk disease in the immune effector therapy era in multiple myeloma.Frontiers in oncology · 2026Review
- Emerging precision medicine in multiple myeloma: clinical and preclinical landscape of T cell, natural killer cell, and macrophages engaging multi-specific antibodies.Frontiers in immunology · 2026Review
- Recent Updates and Advancements in the Diagnosis and Management of Plasma Cell Dyscrasias.Cureus · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroundTalquetamab is the first approved G protein-coupled receptor family C group 5 member D-targeting bispecific antibody for the treatment of triple-class exposed relapsed/refractory multiple myeloma (RRMM) on the basis of results from the phase 1/2 MonumenTAL-1 study (ClinicalTrials.gov identifiers NCT03399799 and NCT04634552). This study describes patient-reported outcomes (PROs) among patients who received talquetamab in MonumenTAL-1.
methodsPROs were assessed in phase 2 of MonumenTAL-1. Patients had RRMM with ≥3 prior lines of therapy (proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies). Patients included in these analyses received talquetamab 0.8 mg/kg every other week. PRO assessments included European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), EuroQol 5-Dimension 5-Level Visual Analogue Scale (EQ-5D-5L VAS), and Patient Global Impression of Severity (PGIS).
resultsAs of January 29, 2024, PRO data were available for 118 patients who received ≥1 dose of talquetamab. Compliance for completion was >95% of patients at baseline and >80% at most posttreatment visits. After an initial worsening in most PROs from baseline through cycle 1, patients reported improvements with continued treatment. At cycle 21, least-squares mean change from baseline showed improvements in global health status (4.9 points) and emotional functioning (12.5 points), along with reductions in pain (11.4 points) and fatigue (4.0 points). The proportion of patients with clinically meaningful improvements or no change from baseline increased throughout treatment. EQ-5D-5L VAS and PGIS scores demonstrated improvement in health-related quality of life.
conclusionsThese PRO results complement the efficacy and safety profile of talquetamab, which highlights talquetamab as a viable treatment option for patients with triple-class exposed RRMM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.